English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 18033/20233 (89%)
造訪人次 : 23239511      線上人數 : 314
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/32520


    標題: Clinical Benefit of Empiric High-Dose Levofloxacin Therapy for Adults With Community-onset plates Enterobacteriaceae Bacteremia
    作者: Lee, Ching-Chi
    Yang, Chao-Yung
    Lee, Chung-Hsun
    Hsieh, Chih-Chia
    Hong, Ming-Yuan
    Hung-Jen Tang(湯宏仁)
    Ko, Wen-Chien
    貢獻者: Tainan Sin Lau Hosp, Dept Adult Crit Care Med
    Chang Jung Christian Univ, Coll Hlth Sci, Grad Inst Med Sci
    Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Emergency Med
    Natl Cheng Kung Univ, Coll Med, Dept Med
    Chi Mei Med Ctr, Dept Med
    Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr
    Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Internal Med
    關鍵字: bacteremia
    defervescence
    empiric therapy
    Enterobacteriaceae
    high-dose
    levofloxacin
    日期: 2019-10
    上傳時間: 2020-07-29 13:48:19 (UTC+8)
    出版者: ELSEVIER
    摘要: Purpose: Levofloxacin is commonly prescribed to treat varied community-acquired gram-negative infections; knowledge of the therapeutic efficacies of high-dose (HD) administration is helpful to improve patient care. Methods: In this 6-year cohort, adults with community-onset Enterobacteriaceae bacteremia were retrospectively studied in 2 hospitals. To overcome the confounding factors in the dosage choice of empiric administration, patients receiving empiric intravenous HD (750 mg/d) therapy were matched with those receiving the conventional dose (CD; 500 mg/d) by using individual propensity scores, calculated by the independent predictors of 30-day crude mortality. Findings: Initially, more patients with critical illness (Pitt bacteremia score [PBS] >= 4) at bacteremia onset and comorbid malignancies and the higher 15- and 30-day mortality rate were recorded in 136 patients receiving HD therapy, compared to 103 receiving CD therapy. After appropriate matching, differences in patient demographic and clinical characteristics between the HD (n = 103) and CD (n = 103) groups were nonsignificant. Consequently, crude mortality rates at 3, 15, or 30 days after onset of bacteremia did not differ. However, the period of time to defervescence, total intravenous antimicrobial administration, and hospital stay was shorter in the HD group than in the CD group. Similarly, regardless if patients had more critical illness (PBS >= 2) or stabilized illness (PBS <2), the advantage of empiric HD therapy on defervescence remained significant. Within 60 days after discontinuation of intravenous levofloxacin therapy, the proportion of recurrent bacteremia, posttreatment overall infections, and posttreatment crude mortality was similar between the HD and CD groups. (C) 2019 Published by Elsevier Inc.
    關聯: Clinical the rapeutics, v.41, n.10, pp.1996-2007
    顯示於類別:[保健營養系(所) ] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    index.html0KbHTML928檢視/開啟


    在CNU IR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋